Stéphane Bancel Usa India Britain covid-19 vaccine Target Stéphane Bancel Usa India Britain

Moderna starts study of hybrid Covid vaccine targeting Omicron

Reading now: 449
www.livemint.com

in the phase 2 study of Omicron-specific bivalent booster candidate, which combines the company’s current Covid-19 vaccine.  "We are pleased to begin this study of our bivalent booster candidate that includes our Omicron-specific candidate and the Moderna COVID-19 vaccine.

Our mRNA platform allows us to pivot with speed and flexibility to create a bespoke vaccine to target new variants as they arise," said Stéphane Bancel, chief executive officer of Moderna. "Our goal has been to remain ahead of the virus and we are committed to generating and sharing data with public health authorities as they prepare for the fall booster season," the Moderna CEO added.

This extension of an earlier study will evaluate the immunogenicity, safety, and reactogenicity of the Omicron-specific bivalent booster candidate as a single booster dose in adults aged 18 years and older who previously received the two-dose primary series of COVID-19 vaccine and a booster dose at least three months ago.

The company expects to enroll 375 participants, which will be conducted at approximately 20 sites in the US. Separately, Moderna said it is evaluating Omicron-specific booster candidate in a phase 3 study in the UK in collaboration with the National Institute for Health Research (NIHR).

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA